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Abstract

An ideal cancer gene therapy would
selectively destroy the cancer nodules with negligible effects
on the surrounding not yet compromised tissue. This would
be possible if the targeted genes are in command positions in
the cancer but not in the normal cells. Logic dictates that,
while being strongly protected by the homeostatic
mechanisms, expression of a commander gene governs most
major functional pathways by regulating the expression of
numerous other genes. Owing to the cancer dependence on
race, sex, age, genetic heritage, medical history,
environmental and lifestyle associated risk factors each
patient has most likely a distinct, dynamic and never
repeatable set of commander genes. Here we introduce the
“gene commanding height” as a measure of gene rank in the
cell hierarchy and test our procedure on a surgically removed
metastatic clear cell renal cell carcinoma. Results indicate
that each histopathologically distinct region has a unique set
of commander genes and that cancer cell commanders are in
low positions in normal cells. We believe that the genomic
oncology should identify the cancer cell commander genes
of the individual patient instead of testing for the biomarkers
selected from most frequently altered genes in large
populations.
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Commander Gene, Gene Commanding
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1. Introduction
Most cancers are caused by random changes in the
genome of individual cells [1, 5]. Tumors are not
homogeneous but composed of several subpopulations of
morphologically distinct cell types, pointing to different
genetic alterations. Cancer development depends on race,
sex, age, life-style, medical history, and environmental
exposure to certain toxins and radiations [6]. A very
important yet not well understood role in cancerization is
played by the inhabiting microbiota (e.g. [7]) modulated by

one’s diet. However, most meta-analyses have not
considered a well-stratified population with respect to all
combinations of major risk factors. Instead, they collated
data from several laboratories whose different platforms,
protocols and data processing procedures question the
significance (e.g. [8-13])
Numerous genomics labs are racing to identify the gene
whose mutation, epigenetic alteration or/and regulation of
the expression level indicate with reasonable predictive
value the occurrence and development of a particular disease
(e.g. [14, 15]). Such “biomarkers” are selected from the most
frequently altered genes in meta-analyses of large population
cohorts. The millions of mutations in the genome of cancer
cells [16] result in altered sequence and/or abundance of
mRNA transcribed from thousands of affected genes.
Although neglected and presumably not with equal effects,
each of these alterations may contribute to the cancer
phenotype. Experimental evaluation of the phenotypic
effects of a particular gene alteration is almost impossible
given that any gene manipulation affects hundreds of other
genes as reported in countless studies on genetically
engineered animals and cell lines (including ours, e.g. [17]).
Owing to their astronomic number there is no way to
consider and validate all possible combinations of genes
whose mutation/regulation might be indicative for a
particular form of cancer in each population category (e.g.
there are >17 trillion distinct 10-gene panels selectable from
100 candidates!). Because of this, no bio-assay can, in
principle, provide a reasonable predictive value in
diagnosing a sporadic cancer [18-21]. There are essentially
innumerable combinations of epigenetic alterations that
regulate the transcriptome in spite of claims that a particular
DNA hypermethylation is a pan-cancer marker [22].
Nonetheless, each cell should be governed by a set of
commander genes whose right expression is critical for the
cell phenotype, survival, proliferation or/and integration in a
multicellular structure. As such, expression of a commander
gene should regulate expression of numerous other genes
while being highly protected by cell homeostasis. The strong
protection makes a commander gene less alterable by the
random alterations caused by the stochastic nature of the
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chemical reactions and therefore not selectable as a disease
biomarker by the Principal Component Analysis [23].
However, when it happens, alteration of a commander gene
reverberates through the entire cell transcriptome and is
amplified by the alteration of the genes it commands. If the
commander genes in cancer cells are commanded in normal
ones then their smart manipulation might selectively destroy
the cancer cells from a heterogeneous tumor and may have
lesser effect on healthy tissue. Because of unique
combinations of risk factors, the gene chain of command in
the same type of cancer phenotype is most likely different
from person to person.
In previous papers, we defined the genomic fabric [24-28]
of a given biological process as the transcriptome associated
with the most interconnected and stably expressed gene
network responsible for that process. We reported that
expression level, control and coordination of fabric genes
depend on tissue, race/strain, sex and sex hormones, age and
environment etc. and change during development,
progression of a disease, and in response to various stimuli.
The Genomic Fabric Paradigm (GFP) switches focus from
the most frequently altered genes in numerous
phenotypically similar individuals (biomarkers) to the most
important genes for the individual patient.
Using GFP, its advanced analytical tools and a new
transcriptomic measure “gene commanding height” we here
propose a procedure to identify the command genes which
we believe are the most legitimate targets for personalized
anticancer therapy.

2. Materials and Methods
2.1. Strategy
Our strategy relies on collecting small pieces from
histopathologically distinct regions of a tumor, split each
piece in four and profile the transcriptome of each quarter.
The splits (biological replicas) are like one system tuned to
slightly different local conditions. The procedure is
illustrated with a metastatic case of clear cell renal
carcinoma.
Profiling four biological replicas provides enough
accuracy for three independent measures of each gene: i)
average expression level, ii) expression variability and iii)
expression coordination with every other gene. Comparing
the average expression levels of individual genes in a tumor
cancer sample with respect to the adjacent normal tissue
identifies the significantly regulated and turned on/off genes
in that sample. Expression variability among biological
replicas is an indirect estimate of the control exerted by the
homeostatic mechanisms to stabilize the abundance of key
transcripts within narrow interval regardless of
environmental fluctuations. Most likely the commanded
genes have the expression levels tied to the commander’s.
Therefore, the commanded genes are among the

synergistically and antagonistically expressed partners of the
commander and can be identified by the significant pair-wise
Pearson correlation of their expression levels within
biological replicas.
2.2. Tumor Samples
We have profiled the gene expression in frozen specimens
from a 74y old man with metastatic clear cell renal cell
carcinoma. The study was part of a project of Dr. DA Iacobas
approved by New York Medical College’s and Westchester
Medical Center (WMC) Committees for Protection of
Human Subjects, commonly known as Institutional Review
Boards (IRBs) by L-11,376. The approval granted access to
frozen cancer specimens from the WMC Pathology Archives
and depersonalized pathology reports, waiving patient’s
informed consent.
Four samples were collected from each of NORmal cortex
and two Primary Tumor regions A and B (PTA, PTB) of the
right kidney and from a metastatic chest wall lesion (MET).
PTA and PTB regions were selected based on their gross
anatomical differences. The samples were small (2 – 8 mm3)
and chosen to be as homogeneous as possible. However,
cells of different phenotypes were not completely eliminated
and expression of their genes might have affected the
reported results.
2.3. Microarray
We used our standard protocol for extraction, reverse
transcription, fluorescent labeling and hybridization with
Agilent 4x44k two color gene expression human microarrays
of total RNA [29]. Raw and processed data complying with
the Minimum Information About a Microarray Experiments
(MIAME) have been deposited and are available at [30].
A gene was listed as differentially expressed between the
regions α and β if the absolute expression ratio x exceeded
the unit by twice of the pooled expression variabilities of that
gene in the two regions (Eq. 1)

(

xi( α ,β ) > 1 + 2 ( CVi ( α ) ) + ( CVi (β ) )
2

2

)

(1)

where CVi(α/β) is the coefficient of variation in the indicated
region.
The differential expression was considered as significant
if the p-value of the heteroscedastic t-test computed with a
Bonferroni type correction applied to the redundancy group
of spots probing the same transcript [30] was less than 0.05.
The method to identify the regulated genes was validated in
many of our previous transcriptomic studies by comparing
the microarray results with those obtained by qRT-PCR or
Western blotting (e.g.: [17, 32, 33])
Expression control of a gene in a particular region was
computed as the complement to 100% of the coefficient of
variation of the normalized expression levels in the four
biological replicas profiled in that region.
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Expression coordination of two genes i and j in a region α and CDK9 were up-regulated in both PTA and MET but not
was determined by computing the pair-wise Pearson in PTB, perhaps explaining why the faster growing PTA
correlation coefficient ρijα between their corresponding (log2) cells metastasized to the chest wall.
levels in the biological replicas of that region.
Gene Commanding Height (GCH) score of gene i in
region α was computed as:
CVi ( α )

N
 4

2
exp
ρij( α ) ) − 1
(

∑
(α)
CVi
 N − 1 =j 1, j ≠i

α =NOR, PTA, PTB, MET

GCH i( α )
=

Γ

(2)

where N is the number of all analyzed distinct genes.

3. Results
3.1. Clear Cell Renal Cell Carcinoma CCRCC is
Transcriptomically Heterogeneous
Figure 1A presents the percentages of differentially
expressed genes when NORmal, Primary Tumor A, Primary
Tumor B and METastatic regions (NOR, PTA, PTB and
MET) were compared to each other. With respect to NOR,
15.0% of the genes were significantly up- or down-regulated
in PTA, 11.7% were regulated in PTB and 23.8% in MET.
Experimental data indicate that MET originated from PTA
(only 3.6% differentially expressed genes) rather than from
PTB (23.8% differentially expressed genes). Interestingly,
more genes were differentially expressed between the two
primary tumor regions (19.4%) than between each tumor
region and the reference tissue. The differences between
PTA and PTB and similarities between PTA and MET are
evident in Figure 1B, which presents the regulation of cancer
biomarkers selected from [34].
3.2. Cell Proliferation and Spread Increased in CCRCC
to Counter Up-regulation of the Immune Response
Phenotypic changes beyond cut-off limits trigger an
immune attack to kill and eliminate aberrant cells. This is
consistent with our finding that 19% of the 130 genes
involved in the chemokine signaling [35] were regulated in
PTA, 11% in PTB and 18% in MET. These percentages
indicate also that the immune response was lower in PTB
than in PTA and MET, concordant with all other findings of
less severe CCRCC in PTB than PTA. However, although
attacked by the immune system, cancer cells acquire
proliferation rates that exceed tissue control mechanisms.
Indeed, in all three cancer regions we found up-regulation of
the cyclins CCNB1IP1, CCNC and CCND2 while none of
the cyclin-dependent kinase inhibitors was affected.
Cyclin-dependent kinases CDK13, CDK4, CDK5, CDK5R1

Figure 1. (A) Percentages of differentially expressed genes when
comparing the groups to each-other. Note the significantly lower
percentage of differentially expressed genes between PTA and MET. (B).
Regulation of some “known” cancer biomarkers. Red/green/blank square
indicates whether that gene was significantly up-/down-/not regulated in
the indicated region with respect to the control tissue.
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In addition to increased proliferation of cancer cells,
cancer-inducing molecular factors can spread to neighboring
cells via gap junction channels. We found that GJA4 gene
encoding the vascular gap junction protein connexin 37
(Cx37) was up regulated by 2.1x in PTA, 2.0x in PTB and
2.4x in MET. GJB2, encoding Cx26, was 2.1x up-regulated
in PTA, 1.8x down-regulated in PTB and 2.4x up-regulated
in MET, while GJC1, encoding Cx45, was not regulated in
PTA and MET but 2.6x down-regulated in PTB.
Down-regulation of two important connexin genes in PTB
suggests not only less synchronization of cancer
development in the neighboring cells but also different
tumorigenesis mechanisms than in PTA and MET regions.
3.3. CCRCC Increased the Overall Expression Control
and Coordination
The overall expression variability among biological
replicas was significantly reduced in all CCRCC groups with
respect to NOR group indicating increased control of
transcript abundances (Figure 2A). Analysis of expression
correlation (principle presented in Figure 2B) also revealed
substantial increases in expression coordination (both
synergistic and antagonistic) in all CCRCC groups with

respect to NOR samples (Figure 2C). Note that both
expression control and expression coordination had smaller
increases in the region also exhibiting the least expression
regulation (PTB).
3.4. CCRCC Rearranged the Gene Networks
Expression coordination of two genes indicates whether
they are inter-connected in a gene network. We found that
all pathways analyzed so far (apoptosis, chemokine
signaling, mTOR signaling, VEGF signaling, oncogenes
and mitochondrial genes) as well as their interplays
exhibited significant network rearrangement. Figure 3
illustrates the expression inter-coordination for a group of
20 mitochondrial ATP-synthases. CCRCC not only
increased the overall expression coordination of these genes,
but it also modified their partnerships, indicating changes in
mitochondrial
function.
For
instance,
ATP6
(mitochondrially encoded ATP synthase 6) has no
significant coordination partner in NOR but it is
independently expressed with ATP5G2. However, it has 4
synergistically expressed partners in PTA including
ATP5G2, 1 in PTB and 11 in MET.

Figure 2. CCRCC increases expression control and coordination. (A). Average control of gene expression level among biological replicas of the four
regions. The overall reduction of the coefficient of variation (CV) was evident for all genes as well as for the separately analyzed pathways. Note that CV
reduction was smaller for PTB samples than for PTA and MET ones. (B). Examples of genes that are synergistically (KDR = kinase insert domain receptor
(a type III receptor tyrosine kinase)), antagonistically (CDC42 = cell division cycle 42) and independently (MAPKAPK2 = mitogen-activated protein
kinase-activated protein kinase 2) expressed with VEGFA (transcript variant 1) in PTB. Numbers above linear regression lines are the Pearson pair-wise
correlation coefficients between the sets of (log2) expression levels within biological replicas of the correlated genes. (C). Coordination percentages when all
genes are considered and when the analysis is restricted to separately analyzed groups of genes/pathways. Note the increase of coordination percentage in
cancer samples. Observe also that the mitochondrial genes were the most affected.
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Figure 3. Expression coordination among 20 mitochondrial ATP-synthases in the four profiled regions. A red/blue/(dashed) black line indicates that
the linked genes are (p < 0.05) synergistically, antagonistically or independently expressed, while a missing line means lack of statistical evidence to
characterize the coordination. Percentages of coordination for these genes were respectively: 64% (NOR), 82% (PTA), 70% (PTB) and 78% (MET). Note
the increase of coordination in cancer samples and the changes in expression pairing. Gene symbol in a square box (e.g., ATP5L2) indicates significant
up-regulation in that region with respect to the normal kidney tissue.

Figure 4. Gene Commanding Height. (A) GCH of several “known” cancer biomarkers, oncogenes, mitochondrial genes (MIT) and genes involved in
apoptosis and chemokine signaling (CHE). Color arrows indicate the command genes in each region. (B) Relative GCH of selected command genes in
regions other than they command.
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3.5. Histopathologically Distinct Regions have Different
Command Genes

the affected gene. GFP characterizes the organizational
principles [36] of the (here) kidney cortex transcriptome for
each individual aiming to determine the critical limits of their
We defined (Eq.2) the Gene Commanding Height (GCH) alteration beyond which there is a spontaneous progression
in a particular region as a composite score accounting for to CCRCC. GFP can use transcriptomic data obtained with
gene expression stability and pooled expression coordination any high throughput gene expression platform when at least
with expressions of other genes within biological replicas of four biological replicas are profiled from each condition.
that region. GCH replaces our Gene Prominence Score
The 4-replicas design provides adequate accuracy for the
[24-27] used to select the most important pathway genes. expression variability and expression control, two additional
Figure 4A presents the commanding heights of several independent measures complementing the average
“known” cancer biomarkers, oncogenes, mitochondrial expression level.
genes (MIT) and genes involved in apoptosis and chemokine
The expression variability can be used to estimate the
signaling (CHE). Results show that the four regions have strength of the homeostatic control of transcript abundance
different gene hierarchies. Interestingly, the mitochondrial [35]. We have speculated that expression of genes that are
GTPBP3 (GTP binding protein 3) tops both PTA (GCH = 79) critical for cell survival, differentiation and integration in a
and PTB (GPS = 95), while PMPCA (peptidase multicellular structure should be under a stricter control.
(mitochondrial processing) alpha, GPS = 74) tops the normal Thus, identification of the most controlled genes in a
tissue. Genes in MET were less clearly differentiated, the top particular condition will indicate the cell “priorities” in that
gene, GNAQ (guanine nucleotide binding protein (G protein), condition. Until a point of no return, the cell is expected to
q polypeptide) GPS = 33, being much less prominent than the increase the overall control of transcript abundances to
command genes in other regions. Interestingly, GNAQ was attenuate/limit the damaging effects of a disease or an
the single biomarkers that exhibited a higher GCH in a environmental stress. However, cells should have genes
cancer region.
whose relaxed control allows easy adaptation to
Importantly, the commanding genes in one region can be environmental fluctuations in each condition and for each
commanded in other regions. Thus, manipulation of such a functional pathway. Interestingly, in many other microarray
gene is expected to have profoundly different effects on studies [31, 33, 37-40] we observed an overall reduction of
histopathologically distinct regions of the tumor. Figure 4B expression variability (indicating increased) control in
presents the percentage from the maximum commanding tissues from diseased, genetically manipulated or stressed
heights of some command genes in other regions than they animals compared to their healthy counterparts. In this study,
command. For this particular patient, GTPBP3 is 15x more we found an overall increase of the expression control in all
powerful in PTA, 18x in PTB and 5x in MET cells than in cancer regions, the smallest increase being observed in the
NOR. In contrast, PMPCA is 6x less powerful in PTA, 11x in region (PTB) having also a smaller number of regulated
PTB and 9x in MET than in NOR region. Therefore, the most genes. Therefore, we believe that increase of the expression
legitimate gene to target for this patient is GTPBP3.
control can be a universal criterion to assess the cancer stage.
The expression correlation indicates what genes can be
included in functional pathways as satisfying a kind of
4. Discussion
“transcriptomic stoichiometry” [38]. When two genes are
This study does not propose new universal biomarkers for synergistically expressed the synthesis rates of the encoded
a particular form of cancer in ALL humans. Since any cancer proteins oscillate in synchrony while these rates manifest
phenotype is the result of all gene alterations (albeit with opposite tendencies when the genes are antagonistically
uneven contributions), and that the number of possible expressed. Expression synergism and antagonism are
combinations of gene alterations is practically infinite, we essential for the performance of functional pathways. We
will never be able to determine the predictive value of all consider the synergistically and antagonistically expressed
combinations in the meta-analysis of a really stratified genes as interconnected in transcriptomic networks.
population. Besides, the biomarkers are selected from the Transcriptomic networks may cross cell borders via
most frequently altered genes in cancer patients (indicating intercellular communication. Thus, regulation of certain
less effort of cell homeostasis to protect their genes in one cell has consequences on the expression level of
sequence/expression as for low plyers) and therefore other genes in neighboring cells, even when neighbors are of
targeting them may not bring much therapeutic benefits. different types [26, 41].
If two genes are independently expressed then there is
Instead, we propose a personalized procedure to identify for
EACH patient the genes whose manipulation might have the little chance that their encoded proteins are part of the same
largest impact on cancer cells because of their regulating the functional pathway. In this study, we found an overall
expression of numerous other genes while being highly increase of expression coordination in all cancer regions.
And, again, the smallest increase was in the least affected
protected by homeostatic mechanisms.
We chose the transcriptomic features because in the end region (PTB). We have also reported increase of expression
almost all kind of mutations affects the transcription level of coordination in previous microarray studies on mice
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subjected to chronic intermittent or constant hypoxia [40].
Therefore, we believe that increases in expression
coordination can be also a universal criterion to assess the
stage of a cancer.
While biomarkers are selected by the Principal
Component Analysis [23] as the most informative subset of
genes for the transcriptomic alterations, GFP uses the
Prominence Gene Analysis [24-26] and the Gene
Commanding Height [28] to establish the gene chain of
command in each condition. Top commander genes are
under stricter protection of the homeostatic mechanisms (and
by consequence among the least alterable) while
coordinating expression of most other genes of the pathway.
This study verified that in a heterogeneous tumor each
histopathologically distinct region has a different set of
commander genes. If a commander gene in cancer cells (like
GTPBP3 here) has significantly lower GCH in normal tissue,
then it could be a potential target to push cell physiological
parameters beyond viable levels in cancer cells leading to
selective destruction whilst preserving function/survival of
cells in normal tissue.
It is possible that certain candidate genes have already
FDA approved targeting therapies. Thus, our procedure
could be a firm step towards a really personalized genomic
cancer medicine.
In order to test the usefulness of our procedure we should
overexpress the commanders that stimulate cancer cell death
and/or tumor suppression or silence the commanders
involved in proliferation and/or spreading. Unfortunately, we
had no possibility to validate for this patient what
manipulation of command genes can do. However,
experiments on several mouse and human cancer cell lines
are underway to test whether manipulation of command
genes affects selectively the cells they command. Further
studies on various cancer types are also necessary to test the
usefulness of the overall expression control and expression
coordination for cancer transcriptomic grading.

5. Conclusions
Instead of using standard gene panels with disputable
predictive value for the current patient, we would likely
profile the cancer nodules, identify the commander genes
and target them.
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